Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Summary

The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response.

Timeline

Start

2006-05

Primary completion

2010-01

Completion

2010-03

Outcome

Outcome not reported

Stopped: “Lack of efficacy. Stopped at first interim evaluation point”

Drugs

Indications